Patents by Inventor Ilan Tsarfaty

Ilan Tsarfaty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucose analogs for diagnosis states
    Patent number: 10736973
    Abstract: Provided are methods and formulations for imaging at least one body region of a subject, employing a glucose analog resistant or inactive to phosphrylation, or which is not a substrate for hexokinase.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: August 11, 2020
    Assignee: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
    Inventors: Gil Navon, Michal Rivlin, Ilan Tsarfaty
  • GLUCOSE ANALOGS FOR DIAGNOSIS OF DISEASE STATES
    Publication number: 20180177898
    Abstract: Provided are methods and formulations for imaging at least one body region of a subject, employing a glucose analog resistant or inactive to phosphrylation, or which is not a substrate for hexokinase.
    Type: Application
    Filed: March 26, 2015
    Publication date: June 28, 2018
    Applicant: TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP
    Inventors: Gil NAVON, Michal RIVLIN, Ilan TSARFATY
  • Met proto-oncogene and a method for predicting breast cancer progression
    Patent number: 6673559
    Abstract: A method for predicting breast tumor metastasis entails determining the amount of met protein in tumor tissue relative to normal breast duct tissue.
    Type: Grant
    Filed: June 26, 1992
    Date of Patent: January 6, 2004
    Assignee: The Government of the United States of America as represented by the Department of Health and Human Services
    Inventors: Ilan Tsarfaty, James H. Resau, Iafa Keydar, Donna Faletto, George F. Vande Woude
  • Method of producing hepatocycte growth factor/scatter factor and related cell lines
    Patent number: 5871959
    Abstract: A method of preventing tumor cell metastasis by inhibiting the binding of hepatocyte growth factor/scatter factor ("HGF/SF") with met proto-oncogene protein is described. A method of producing HGF/SF and a cell line for the production of HGF/SF are also described. The met proto-oncogene tyrosine kinase receptor (Met) and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), ordinarily constitute a paracrine signalling system in which cells of mesenchymal origin produce the ligand, which binds to the receptor that is predominantly expressed in cells of epithelial origin. The method of the present invention disrupts the Met-HGF/SF autocrine signaling that contributes to the tumorigenic process in tumors of mesenchymal origin, such as sarcomas.
    Type: Grant
    Filed: November 18, 1994
    Date of Patent: February 16, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Sing Rong, George Vande Woude, Donna L. Faletto, Ilan Tsarfaty, Marianne Oskarsson